OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

No Link Between Fertility Drugs and Breast, Ovarian and Uterine Cancers

(July 1, 2014)  There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a significant 30-year follow-up study. However, the extended use of clomiphene citrate was associated with a higher risk of breast cancer among women who had used the fertility drug for 12 cycles or more. Gonadotrophins, more commonly used for ovarian stimulation today, were not generally associated with any increased risk, except in a sub-group of women who remained childless after treatment.

The results of the study, which was funded by the National Institutes of Health, were reported at the meeting of the European Society of Human Reproduction and Embryology annual meeting. Previous research has also suggested that IVF does not increase risk of gynecologic cancer.

Click here to read more about this research.